Investors Can Join Regeneron Pharmaceuticals Securities Fraud Lawsuit

Regeneron Pharmaceuticals Securities Fraud Lawsuit

The Rosen Law Firm, a prominent player in global investor rights, has officially announced a class action lawsuit aimed at protecting investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The lawsuit covers transactions involving Regeneron securities that occurred between November 2, 2023, and October 30, 2024. This initiative comes in light of allegations concerning misleading practices that affected investors' stakes in the biopharmaceutical company.

Background of the Case

Investors who purchased Regeneron securities within the specified class period may be entitled to compensation. As per the details shared by the firm, no upfront fees or costs are required from the investors due to a contingency fee arrangement.

Interested parties seeking to participate in this legal action are encouraged to reach out to the Rosen Law Firm. To serve as the lead plaintiff, an individual must file their motion with the court no later than March 10, 2025. The role of the lead plaintiff is critical as it entails acting on behalf of all class members while guiding the litigation process forward.

Why Choose Rosen Law Firm?

The Rosen Law Firm highlights the importance of selecting a legal counsel with a proven track record. They tout their achievements, including being ranked first by ISS Securities Class Action Services for the number of securities class action settlements in 2017. Such accolades provide assurance to potential clients regarding the firm’s capacity and success rates in handling securities law cases. The firm has historically recovered significant amounts for its clients, with more than $438 million amassed for investors in 2019 alone.

Allegations Against Regeneron

The core of the allegations against Regeneron revolves around several misstatements and omissions. These include claims concerning Regeneron's practice of paying credit card fees to distributors. This arrangement was allegedly made under the condition that the distributors would not pass higher prices onto customers buying Eylea, a key product, with credit cards. The lawsuit argues that these payments effectively subsidized prices, thereby misleading investors.

It has also been claimed that Regeneron reported inflated sales figures for Eylea while failing to disclose these price concessions. All these actions purportedly resulted in an inaccurate portrayal of the company’s financial health and misled investors regarding the true nature of its business practices.

As these details surfaced, investors have reportedly experienced losses, giving rise to this legal action. The firm emphasizes that until the class is certified, potential participants are not represented by any counsel unless they engage one independently. Furthermore, maintaining the option to remain an absent class member is also available.

How to Join

To join the class action under Rosen Law Firm’s representation, individuals can visit their website or contact the firm directly. For further instructions or details on how to proceed, interested investors are encouraged to call Phillip Kim, Esq. toll-free at 866-767-3653 or email him at pk@rosenlegal.com.

For those who wish to keep abreast of developments in the case, Rosen Law Firm encourages following them on LinkedIn, Twitter, and Facebook. The firm’s ongoing communication strategies are designed to ensure all class members are informed as the case progresses.

This case underlines the crucial role of investor rights and the importance of transparency in corporate practices, shedding light on the dynamic landscape of securities law.